Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study

NCT07546695 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT07546695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07546695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Observational
Overall status
Recruiting
Start date
February 1, 2026
Completion date
December 31, 2027
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer